E-mail Address. by admin. AGREEMENT AND PLAN OF MERGER AND REORGANIZATION. 371 28. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (âNeuroBoâ) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019.The new combined company, known as NeuroBo ⦠NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (âNeuroBoâ) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019.The new combined company, known as NeuroBo ⦠Gemphire Therapeutics has agreed to merge with biotechnology company NeuroBo Pharmaceuticals in an all-stock transaction. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals PRESS RELEASE GlobeNewswire Dec. 6, 2019, 08:42 AM NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on ⦠NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger. NeuroBo shareholders holds 96.24% stake in the firm. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., ("NeuroBo") and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. Exhibit 2.1 . The merged firm will advance NeuroBoâs clinical-stage drug candidates for neurodegenerative disorders. As previously announced, Gemphireâs stockholders voted to approve the proposals required to complete the merger transaction. BOSTON--(BUSINESS WIRE)--NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019.The new combined company, known as NeuroBo ⦠The merger has been completed between NeuroBo Pharmaceuticals and Gemphire Therapeutics (Credit: Akshay93 from Pixabay) Subscribe to our email newsletter The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ⦠Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company, Stocks: GEMP, release date:Jul 24, 2019 Posted on 01/10/2020 342 . FIRST AMENDMENT TO. Gemphire Therapeutics Inc. and Boston-based NeuroBo Pharmaceuticals Inc. have agreed to a deal that will result in Gemphire changing its name to NeuroBo Pharmaceuticals. ... NeuroBo Pharmaceuticals complete Gemphire merger. The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing conditions. Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company. Read full article. 13 January 2020 (Last Updated January 13th, 2020 10:39) Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals, Stocks: GEMP,NRBO, release date:Dec 30, 2019 January 10, 2020. in Buzz. January 10, 2020, 5:00 PM The pending merger between Gemphire Therapeutics Inc. (GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing conditions. ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) â The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is ⦠Posted on 07/24/2019 56 THIS FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this âFirst Amendmentâ) is entered into and made effective as of October 29, 2019 (the âEffective Dateâ), by and among GEMPHIRE THERAPEUTICS INC., a Delaware corporation (âParentâ), GR MERGER SUB INC., a ⦠NeuroBo Pharmaceuticals has completed its previously announced combination with Gemphire Therapeutics. The move comes as NeuroBo plans to start a ⦠After the merger, NeuroBo investors will own 95.94% of the new company, while Gemphire shareholders will own around 4.06%. Article Stock Quotes (2) Comments (0) FREE Breaking News Alerts from StreetInsider.com! NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. BOSTON--(BUSINESS WIRE)--Jan 10, 2020--NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (âNeuroBoâ) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger. The pending merger between Gemphire Therapeutics Inc. (NASDAQ: GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, ⦠On a pro forma basis and based upon the number of shares of Gemphire common stock to be issued in the merger, the pre-merger Gemphire shareholders will own approximately 4.06% of the post-merger combined company and the pre-merger NeuroBo investors will own approximately 95.94% of the post-merger combined company on a fully-diluted basis. The merged company will focus on the development of NeuroBoâs clinical-stage drug candidates for the treatment of neurodegenerative diseases. As part of the merger, Gemphire stockholders received non-transferable contingent value rights (CVRs) entitling the holders to receive in aggregate, after the ⦠NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger. NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger.